Biotechnology and therapeutic development by Inhibrx Biosciences
Inhibrx Biosciences targets research advances at ASCO26 to accelerate new cancer treatments
Inhibrx Biosciences is actively participating at ASCO26, signaling its commitment to advancing research in oncology. The company invites attendees to visit Booth #37116 to learn more about its ...
INBRX106 trial update signals pipeline progress at Inhibrx Biosciences
Inhibrx Biosciences has announced a clinical update for its investigational therapy INBRX106 in first-line head and neck cancer. The company revealed new information via a press release, ...
Inhibrx Biosciences urges sustained research to accelerate oncology breakthroughs
Inhibrx Biosciences calls for sustained scientific research as an essential driver of breakthroughs in oncology. The company points to the importance of continued investment in understanding ...
Inhibrx Biosciences commits to sustainability with new Earth Day measures
Inhibrx Biosciences marked Earth Day this week by unveiling a series of green initiatives aimed at strengthening its workplace culture. The company encouraged intentional connections among team ...
Inhibrx Biosciences joins AACR Annual Meeting to advance global oncology research
Inhibrx Biosciences announced that its team is attending the AACR Annual Meeting 2026, one of the leading gatherings for the global cancer research community. The company is using the conference ...
Inhibrx Biosciences forges partnerships at Colorado sarcoma symposium
Inhibrx Biosciences is participating in the 2nd Annual Rocky Mountain Sarcoma Symposium in Colorado, where the company is engaging with clinicians and researchers to discuss the latest ...
Inhibrx Biosciences supports Swedish sarcoma research with Sarcoma Day initiative
Inhibrx Biosciences is demonstrating its commitment to rare cancer research by supporting the Swedish Sarcoma Patient Advocacy Association’s Sarcoma Day, held on April 17. The initiative aims ...
Inhibrx Biosciences advances efforts targeting rare sarcoma cancers
Inhibrx Biosciences is intensifying research to tackle sarcoma, a rare group of cancers that form in connective tissues such as bone and soft tissue. The company is focusing on innovative ...
Inhibrx Biosciences partners with Sarcoma Alliance to advance patient education resources
Inhibrx Biosciences has announced a new industry collaboration with the Sarcoma Alliance, aiming to bolster education and resources for the sarcoma patient community. The company stated that its ...
Inhibrx Biosciences spotlights INBRX-106 research at ICHNO2026 in Seville
Inhibrx Biosciences is participating in ICHNO2026 in Seville, Spain, bringing its research focus to the forefront within the global oncology community. The company is highlighting ongoing ...
Inhibrx Biosciences advances sarcoma research with ozekibart trial results
Inhibrx Biosciences has unveiled new developments in sarcoma research, particularly focusing on their ozekibart (INBRX 109) trial in chondrosarcoma. These recent advancements underscore the ...
Inhibrx Biosciences boosts MSTS 2025 with platinum sponsorship
Inhibrx Biosciences is reinforcing its commitment to cancer research by supporting the 2025 MSTS Annual Meeting as a Platinum Sponsor. This move highlights Inhibrx's ongoing work in the field of ...
Inhibrx Biosciences unveils preclinical progress in glioblastoma treatment
Inhibrx Biosciences recently participated in the SNO Annual Meeting in Honolulu. The company presented preclinical data investigating ozekibart (INBRX-109) in glioblastoma models. This ...
Inhibrx supports CTOS2025 spotlight on chondrosarcoma
Inhibrx Biosciences has announced its commitment as a Platinum Sponsor for this year's CTOS2025 Annual Meeting. The focus of this year's meeting is on chondrosarcoma, which has been selected as ...
Inhibrx Biosciences shares promising chondrosarcoma trial results
Inhibrx Biosciences has announced promising outcomes from its ChonDRAgon registrational trial. The trial focused on testing the intervention of ozekibart, known as INBRX109, within individuals ...
